In the original publication, Figure 3 was published incorrectly with errors. In Fig. 3 , the ''Not defined*'' labels should appear in the 'Insulin Glargine U100' row of the table beneath the figure. In place of these the values '41,530' and '57,642', respectively, should appear in the IDegLira row of the table beneath the figure. It has been corrected and the correct version is provided below.
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